Novo Nordisk, Cellartis partner to develop insulin-producing cells from human stem cells
GOTHENBURG, Sweden Danish drug maker Novo Nordisk has partnered with Swedish biotech Cellartis and Lund University to use human stem cells to develop cells that produce insulin for patients with diabetes, Cellartis announced Thursday.
The collaboration aims to develop the cells as a treatment for diabetes and, in the long run, a cure for the disease.
Under the agreement, Novo Nordisk will get exclusive rights to further develop and commercialize potential products for treating diabetes, while Cellartis will acquire exclusive rights to develop and commercialize certain other products developed under the collaboration.
Nerviano partners with Genentech to develop anticancer drugs
NEW YORK A company that develops cancer drugs has announced a multi-year collaboration with Genentech.
Nerviano Medical Sciences said that it would collaborate with South San Francisco, Calif.-based Genentech to search for antibody drug compounds to develop anticancer drugs. It is the second agreement between Genentech and NMS in less than a year, NMS said.
Genentech will have exclusive rights to fully develop and commercialize licensed products, while NMS will primarily synthesize and manufacture drug reagents.
More Americans cutting back on prescription medications
NEW YORK Economic difficulties are causing more Americans to forego prescription drugs, according to The New York Times.
Costs for housing and food are trumping costs for drugs, and some patients have stopped taking drugs for chronic conditions such as osteoporosis and high cholesterol. Some drug makers have reported decreases in sales of certain drugs, while IMS Health has reported reductions in prescriptions being dispensed.
The Times reported that the trend could cause increases in complications from chronic disease.